Skip to main content
. Author manuscript; available in PMC: 2009 Sep 28.
Published in final edited form as: J Rheumatol. 2008 Sep 1;35(10):1966–1971.

TABLE 1.

BASELINE CHARACTERISTICS
Duration of RA <3yrs 3–5 yrs >5yrs p-value
Number Patients 150 155 584
Age (years), (SD) 56 (14.6) 56 (13.7) 60 (12.0) <0.001
White % 82 84 84 NS
College Education 44 48 43 NS
Female % 77 75 77 NS
RF+ ever % 75 76 77 NS
Prednisone Dose (mg/day), (SD)
[of patients using]
5.6 (2.9)
N=64
6.0 (2.9)
N=54
5.6 (2.9)
N=247
NS
mHAQ (0–3), (SD) 0.57 (0.5) 0.47 (0.4) 0.61 (0.5) 0.005
SJC (28), (SD) 6.0 (6.3) 6.8 (6.3) 6.5 (6.0) NS
TJC (28), (SD) 5.8 (6.9) 5.8 (6.4) 5.8 (6.2) NS
ESR (mm/hr), (SD) 23 (18.4) 25 (19.7) 28 (22.8) 0.037
DAS28, (SD) 3.9 (1.5) 4.0 (1.3) 4.3 (1.4) 0.017
CDAI (0–76), (SD) 18 (13.9) 18 (12.6) 20 (12.9) NS
# DMARDs Ever, (SD) 1.08 (0.9) 1.9 (1.5) 2.55 (1.9) <0.001
DMARD Frequency Index* (SD) 0.80 (0.7) 0.51 (0.4) 0.19 (0.2) <0.001
CHANGE FROM BASELINE TO FOLLOW-UP 6–12 MONTHS LATER
Duration of RA <3yrs 3–5 yrs >5yrs p-value
Months from Initiation of new
DMARD, at baseline (SD)
9.2 (1.8) 9.3 (1.7) 9.3 (1.7) NS
Number Patients 150 155 584
Change in Prednisone Dose
(mg/day), (SD)
−0.7 (2.6) −0.3 (2.7) 0.01 (2.8) 0.016
Discontinued Prednisone (%) 15 5 6 0.001
mHAQ (0–3), (SD) −0.13 (0.5) −0.03 (0.4) −0.07 (0.4) NS
SJC (28), (SD) −1.4 (6.6) −1.8 (5.8) −1.6 (5.7) NS
TJC (28), (SD) −1.6 (7.8) −1.0 (6.6) −1.4 (6.8) NS
ESR (mm/hr), (SD) −1.6 (12.3) −1.1 (16.8) −2.3 (16.4) NS
DAS28, (SD) −0.29 (1.4) −0.39 (1.4) −0.46 (1.4) NS
CDAI (0–76), (SD) −4.3 (16.4) −3.4 (13.6) −4.6 (13.7) NS
DMARD Added % of Patients 8.0 5.2 5.8 NS
DMARD Discontinued % of Patients 10.7 14.2 9.8 NS
*

DMARD Frequency Index= Number of DMARDs ever used divided by disease duration in years. For 877 observations (12 missing because duration was “0”); mean = 0.35 (SD 0.42), median = 0.2, range = 0–3.33